Bone Biologics Corporation
BBLGNASDAQHealthcare● Active
$1.25
+$0.00(+0.10%)
Market Cap$2244075
P/E Ratio—
52W High$6.75
52W Low$1.05
Bone Biologics Corporation (BBLG) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BBLG · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.43
Est. -$0.54 · +20.4%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▲ Beat EPS✓ 3-Quarter EPS Beat Streak
BBLG reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.19
Rev. $0.35B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.19
Rev. Est.$0.35B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.39 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 14, 2026 | -$0.54 | -$0.43 | +20.4% | — | — | — |
| ▲ Q1 FY2026 | Mar 2, 2026 | -$0.34 | -$0.14 | +58.8% | — | — | — |
| ▲ Q4 FY2025 | Nov 14, 2025 | -$1.23 | -$0.37 | +69.9% | — | — | — |
| ▼ Q3 FY2025 | Aug 14, 2025 | -$0.58 | -$1.33 | -129.3% | — | — | — |
| ▼ Q2 FY2025 | May 12, 2025 | -$0.48 | -$1.92 | -300.0% | — | — | — |
| ▲ Q1 FY2025 | Mar 5, 2025 | -$0.65 | -$0.61 | +6.2% | — | — | — |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$3.60 | -$14.22 | -295.0% | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.39
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Beat
EPS Actual
-$0.43
EPS Est.
-$0.54
EPS Surpr.
+20.4%
Revenue
—
Q1 FY2026
Mar 2, 2026Beat
EPS Actual
-$0.14
EPS Est.
-$0.34
EPS Surpr.
+58.8%
Revenue
—
Q4 FY2025
Nov 14, 2025Beat
EPS Actual
-$0.37
EPS Est.
-$1.23
EPS Surpr.
+69.9%
Revenue
—
Q3 FY2025
Aug 14, 2025Miss
EPS Actual
-$1.33
EPS Est.
-$0.58
EPS Surpr.
-129.3%
Revenue
—
Q2 FY2025
May 12, 2025Miss
EPS Actual
-$1.92
EPS Est.
-$0.48
EPS Surpr.
-300.0%
Revenue
—
Q1 FY2025
Mar 5, 2025Beat
EPS Actual
-$0.61
EPS Est.
-$0.65
EPS Surpr.
+6.2%
Revenue
—
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$14.22
EPS Est.
-$3.60
EPS Surpr.
-295.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.33 | $-0.33 | $-0.33 | 1 |
| Q3 FY2026 | $-0.36 | $-0.36 | $-0.36 | 1 |
| Q2 FY2026 | $-0.39 | $-0.39 | $-0.39 | 1 |
| Q1 FY2026 | $-0.43 | $-0.43 | $-0.43 | 1 |
| Q4 FY2025 | $-0.34 | $-0.34 | $-0.34 | 1 |
| Q3 FY2025 | $-0.37 | $-0.37 | $-0.37 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 14, 2026 | +20.4% | $1.30 | $1.27 | -2.31% |
| ▲ Q1 FY2026 | Mar 2, 2026 | +58.8% | $1.15 | $1.19 | +3.48% |
| ▲ Q4 FY2025 | Nov 14, 2025 | +69.9% | $1.70 | $1.60 | -5.88% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -129.3% | $2.35 | $2.35 | +0.00% |
| ▼ Q2 FY2025 | May 12, 2025 | -300.0% | $4.50 | $4.38 | -2.67% |
| ▲ Q1 FY2025 | Mar 5, 2025 | +6.2% | $4.76 | $5.22 | +9.66% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -295.0% | $7.08 | $7.74 | +9.32% |
| ▲ Q3 FY2024 | Aug 9, 2024 | +51.8% | $9.54 | $10.14 | +6.29% |
Q2 FY2026-2.31%
Report Date
May 14, 2026
EPS Beat/Miss
+20.4%
Price Before
$1.30
Price After
$1.27
Q1 FY2026+3.48%
Report Date
Mar 2, 2026
EPS Beat/Miss
+58.8%
Price Before
$1.15
Price After
$1.19
Q4 FY2025-5.88%
Report Date
Nov 14, 2025
EPS Beat/Miss
+69.9%
Price Before
$1.70
Price After
$1.60
Q3 FY2025+0.00%
Report Date
Aug 14, 2025
EPS Beat/Miss
-129.3%
Price Before
$2.35
Price After
$2.35
Q2 FY2025-2.67%
Report Date
May 12, 2025
EPS Beat/Miss
-300.0%
Price Before
$4.50
Price After
$4.38
Q1 FY2025+9.66%
Report Date
Mar 5, 2025
EPS Beat/Miss
+6.2%
Price Before
$4.76
Price After
$5.22
Q4 FY2024+9.32%
Report Date
Nov 14, 2024
EPS Beat/Miss
-295.0%
Price Before
$7.08
Price After
$7.74
Q3 FY2024+6.29%
Report Date
Aug 9, 2024
EPS Beat/Miss
+51.8%
Price Before
$9.54
Price After
$10.14
Avg Beat Reaction+2.25%
Avg Miss Reaction+2.22%
Beat Rate5 / 8 quarters
Largest Move+9.66% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BBLG ends December
Bone Biologics Corporation (BBLG) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.43 — beating the analyst consensus of $-0.54 by +20.4%. BBLG has beaten EPS estimates for 3 consecutive quarters. The next BBLG earnings date is expected around September 1, 2026.
Each quarter, investors track BBLG earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BBLG revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BBLG's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BBLG earnings · 5 questionsBone Biologics Corporation's next earnings report is expected around September 1, 2026. BBLG typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BBLG historically reports after market close (AMC).
BBLG earnings datewhen is BBLG earningsBBLG next earnings datewhen does BBLG report earningsBBLG earnings calendar
▸ Source: FMP · Bone Biologics Corporation SEC filings · US GAAP · Bone Biologics Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026